Adamas Pharmaceuticals Inc. (NASDAQ:ADMS) shares were up 9.1% during trading on Thursday . The stock traded as high as $16.36 and last traded at $16.16, with a volume of 319,076 shares trading hands. The stock had previously closed at $14.81.

Several research analysts recently commented on ADMS shares. Credit Suisse Group AG reissued a “buy” rating on shares of Adamas Pharmaceuticals in a research report on Wednesday, June 22nd. Mizuho reissued a “buy” rating on shares of Adamas Pharmaceuticals in a research report on Thursday, June 23rd. Noble Financial started coverage on Adamas Pharmaceuticals in a research report on Friday, June 17th. They set a “buy” rating and a $25.00 price target for the company. JMP Securities reissued a “buy” rating on shares of Adamas Pharmaceuticals in a research report on Wednesday, June 15th. Finally, Cowen and Company reissued a “buy” rating on shares of Adamas Pharmaceuticals in a research report on Thursday, May 12th. One research analyst has rated the stock with a sell rating, one has given a hold rating and nine have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $33.60.

The firm has a 50-day moving average price of $16.14 and a 200 day moving average price of $16.56. The stock’s market cap is $351.22 million.

Adamas Pharmaceuticals (NASDAQ:ADMS) last issued its earnings results on Tuesday, May 10th. The specialty pharmaceutical company reported ($0.65) EPS for the quarter, beating analysts’ consensus estimates of ($0.76) by $0.11. Equities research analysts expect that Adamas Pharmaceuticals Inc. will post ($3.09) EPS for the current year.

A hedge fund recently raised its stake in Adamas Pharmaceuticals stock. Dimensional Fund Advisors LP increased its position in shares of Adamas Pharmaceuticals Inc. (NASDAQ:ADMS) by 585.5% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 69,411 shares of the specialty pharmaceutical company’s stock after buying an additional 59,285 shares during the period. Dimensional Fund Advisors LP owned about 0.38% of Adamas Pharmaceuticals worth $1,966,000 as of its most recent filing with the SEC.

Adamas Pharmaceuticals, Inc is a pharmaceutical company. The Company is focused on the development and commercialization of therapeutics targeting chronic disorders of the central nervous systems (CNS). Its segment focuses on the development and commercialization of therapeutics targeting chronic disorders of the central nervous system.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.